Coherus Oncology, Inc. (CHRS) vs Cardiol Therapeutics Inc. (CRDL)
A side-by-side comparison of Coherus Oncology, Inc. and Cardiol Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CHRS
Coherus Oncology, Inc.
$1.07HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
CRDL
Cardiol Therapeutics Inc.
$1.34HealthcareDelayed quote: Oct 6, 2026, 11:49 AM EDT
Total return — CHRS vs CRDL
growth of $100 · dividends reinvested · last 8yCHRS -90.8% (-25.8%/yr)CRDL -64.7% (-12.2%/yr)CRDL compounded faster over this window
CHRS CRDL
CHRS vs CRDL: by the numbers
- •CHRS is the larger company ($165M vs $154M market cap).
- •Both run net losses; CRDL's is the smaller (0.00% vs -257.10% net margin).
Metrics side by side
Valuation
| Metric | CHRS | CRDL |
|---|---|---|
| P/S ratio | 3.23 | N/A |
| P/B ratio | 2.70 | 9.09 |
Profitability
| Metric | CHRS | CRDL |
|---|---|---|
| Gross margin | 63.55% | 0.00% |
| Operating margin | -425.72% | 0.00% |
| Net margin | -257.10% | 0.00% |
| ROE | -215.26% | -155.34% |
| ROIC | -135.38% | -165.56% |
Growth (annualized)
| Metric | CHRS | CRDL |
|---|---|---|
| Revenue CAGR (5Y) | -33.60% | N/A |
| Total return CAGR (5Y) | -41.38% | -18.36% |
Frequently asked
- How have CHRS and CRDL total returns compared?
- Over the past 5 years, CHRS delivered -41.38% and CRDL delivered -18.36% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.